<DOC>
	<DOCNO>NCT02583373</DOCNO>
	<brief_summary>The objective study assess safety , tolerability , clinical microbiological efficacy pharmacodynamics patient severe pneumonia cause Streptococcus pneumoniae intravenous administration CAL02 addition standard care antibiotic treatment .</brief_summary>
	<brief_title>Safety , Tolerability , Efficacy Pharmacodynamics CAL02 Severe Pneumonia Caused Streptococcus Pneumoniae</brief_title>
	<detailed_description>Streptococcus pneumoniae frequently identify pathogen community-acquired bacterial pneumonia severe form associate high morbidity mortality , despite pneumococcal vaccine medical treatment ( antibiotic therapy , alone combination ) . Bacterial toxin , pore-forming toxin ( PFT ) pneumolysin ( Streptococcus pneumoniae ) , involve development invasive disease play key role severe fatal complication . CAL02 offer novel therapeutic approach neutralise bacterial toxin , pneumolysin , recognise specific microdomains host cell membrane , call lipid raft .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Pneumonia , Pneumococcal</mesh_term>
	<criteria>Adult male female patient ≥ 18 year ≤ 80 year age Body weight 40140 kg Severe pneumonia cause Streptococcus pneumoniae manage ICU CURB65 score ≥ 3 Streptococcus pneumoniae identification urine antigen test , feasible , Gram+ stain respiratory sample . Written inform consent provide patient , relative designate trusted person and/or accord local guideline Antibiotic treatment &gt; 12 hour IV &gt; 48 hour per o , unless active Streptococcus pneumoniae APACHE II score &gt; 30 point SOFA score &gt; 12 point Inability maintain mean arterial pressure ≥ 50 mm Hg Known hypersensitivity liposomal formulation Patients severe neutropenia lymphoma current anticipate chemotherapy Endstage neuromuscular disorder Patients longterm tracheostomy Current recent participation investigational study Presence pneumococcal site infection Patients know acquire immune deficiency syndrome ( AIDS ) CD4 count &lt; 200 cells/mL Patients know postobstructive pneumonia ( active primary lung cancer another malignancy metastatic lung ) Patients cystic fibrosis , Pneumocystis jiroveci pneumonia , active tuberculosis Patients receive immunosuppressant therapy Patients know liver function deficiency Splenectomised patient Patients experience allergic reaction egg Moribund clinical condition Nursing pregnant woman Women child bear potential use effective contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Pneumonia</keyword>
	<keyword>Streptococcus pneumoniae</keyword>
	<keyword>Pneumolysin</keyword>
</DOC>